Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
are you not worried/alarmed/concerned NWBO left this text out the 10Q flipper
in preparation for publication in a scientific journal and public announcement
?
They removed this from the new 10Q...:
yeah no the market is not that idiotic. I believe in over and under reaction by markets which is always a good moment to enter. NWBO SP however has been on this level for a long time. Mr Market is telling NWBO is not derisked NWBO has a lot to prove still, NWBO is still a risk, and NWBO has still dilution ahead.
Yes I believe a good bunch of longs will exit in the next volume up.
No Im not encouraging anyone to do anything. You see if I, for a moment, believed to posse the power to influence other investors to buy or sell any stock on an anonymous messageboard I would seriously be in need of tranquilizers and psychotics. It would mean I overestimate myself in such a manner I would be in need of serious mental help. Thank goodness I'm sound of mind and in good mental condition so I do not for a moment think that.
You know posts like yours remind me of a part of an article I read today in SA:
I wish for you it will be soon, you have earned it after so many years of being a loyal shareholder.
good grief you really need help
the wet dreams about building out capacity at CRL for the sake of DCVAXL maybe yes maybe no have always annoyed the hell out of me. Why would CRL not have common business sense? Its absurd
all that you just said is utter nonsense. But since I have gone over this many times in the past and this discussion is in the back mirror I have very little energy to help you understand how biotech regulations work. I suggest you start googling and read FDA regs this website is also very helpful and it has helped me in my line of work to cite from for my clients:
https://www.law.cornell.edu/cfr/text/42/11.44
Im 100% convinced a lot is being held up / depends of Journal article has run into problems. Im incredibly worried about this. If the JA would be out of the way we will ee a huge sigh of relief in the SP.
I suspect NWBO management is also in limbo about this. It incredible frustrating
its a fair and balanced to assume they have run into obstacles otherwise the publication would have already appeared given the time-lapse so far, especially with great and wonderful trial results as you say they have,;. Now what is not a fair and balanced assumption but ridiculous speculation is the JA is being held for an RA to approve first.
no BS they are are having trouble getting the JA published. Thats a fact
Hygro,
Its simple nonsense what you state. NWBO did not submit a request to change endpoints' post hoc data. They have submitted an amended SAP 2 years before data lock. Dr Laiu has stated that the FDA had no comments or concerns to the amended endpoints with OS as the primary endpoint. That was 2018.
From what I read you a quite unfamiliar with FDA regulations. The FDA has absolutely NO problem with trials to change endpoints and SAP. The ONLY rule the more or less maintain is that for a trial to change endpoints is done by trial investigators who are objective to the trial.
Your claim the FDA does not allow endpoints change, and your claim NWBO changed endpoints/SAP after data lock is a huge pile of BS. Changing a government website is not the same as submitting an amended SAP.
By the way FYI the FDA also allows trials to change endpoints and SAP AFTER data lock.
So by not responding the FDA accepted OS as the primary endpoint, and OS as the endpoint has been met. The trail, therefore, is a success.
A I don’t believe you. And the example u gave has zero todo what we were discussing
B still no example of a small investment of an investors group paying premium direct to a listed company for common or prefs without any other incentive (which I was talking about) where as they could have bought at the open market. Crickets
Then you don’t mind giving one example of a small investment above market price direct with the listed company. Loud m. Crickets
You twist my words what I said so you post is uninteresting
Btw I don’t belt any word of your tuff stories being the great million dollar share trader. In my experience often those boosting are the least successful
thats your prerogative its a free county
we have seen the SP run-up time and again without a short squeeze. The only short squeeze I have seen was in Oct 2020 when it run up fast to 2.5$. Buying some C prefs will definitely not upset anyone still short in NWBO it will just indicate to anyone with a short position more dilution is on the way and the premium paid for the Cs you speak off will pocket management.
I said (half) a week, not half a week semantics.
you know when I would laugh my ass off? If Northwest would get MHRA approval for DCVAX L while still not having official PRed TLD while still being in the self-imposed declared quiet period.
Thank you for clearing some things up. So what I understand from what you are saying is that they were not prepared to sell you the C's. Im absolutely sure you are a very loyal long but I dont believe for a second that if they were prepared to sell you the C's you would have agreed to do so against the present common share price. Anyway, they have told you they are not selling to retail, which btw it surprises me they told you about the 3 months hold before converting.
I dont believe a huge short squeeze will happen. I do believe some huge investors may buy into a huge position and set the SP to above 2$ for good AFTER JA/official PR of TLD and MHRA request for approval.
its incredibly irrelevant if the journal article is in expeditated review or not. I am pretty sure they are not almost 2 years after datalock, it's ridiculous to think otherwise.
There are quite some controversies in the trial that needs to be discussed by the reviewers. If these controversies have been discussed here for months on end by some clever posters such as Flipper dont you think the reviews have some similar questions? To name a few of the discussions that have raged here Pseudo Progression, Cross Overs, the peer group, the ECA! compassion etc etc hello of course the reviews have the (same) many questions which need to be answered. Only the reviewers need to settle their question marks in a couple of months and not a few years' time as these discussions were settled here on Ihub.
This company is only then derisked until after the JA has been published and a RA has approved DCVAXL. Until then we remain at low-level MC or we speculate up to fall back down again. Months many months people. I say spring 2023 before this stock is finally out of the headache area.
Thanks :)
Now you are talking nonsense.
The sad thing about NWBO management is, especially Les, is WHILE data is excellent, which everyone knows it is excellent including LP, they are not able to get decent finance. And no selling C's to retailers is NOT a decent finace.
They are stuck in getting the JA published thats what we are waiting for could be many weeks could be months before they finally grow up and publish in JTM.
NWBO can not guarantee the conversion of the C's into the common within any timeframe until after the (A)SM has approved to increase the A/S. That's just a cold hard fact. Like gravity. Dont matter if they have guaranteed similar moves in the past. If they are guaranteeing this to date then they are making promises they may have to break.
Any buyer of Cs should know that
There is anything but a guarantee the Cs can ever be converted into common shares especially in 3 months from now
dont count on it it will be less disappointing when you found out they have not
aah yes its Mexico, my bad too bad ( was looking at it from my iPhone)
Interesting this patent is not for Spain but for all of EU all 27 member states